Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns

•There is currently no licensed medication for NASH. •OCA has provided beneficial effects in NASH, including fibrosis improvement. •Pruritus and adverse effect on LDL-C should be considered in relation to OCA treatment. •More rare side effects and/or ones that may develop over a longer period of time will need to be studied in the context of ongoing...